Calcitonin gene-related peptide, heme oxygenase-1, endothelial progenitor cells and nitric oxide-dependent vasodilation relationships in a human model of angiotensin II type-1 receptor antagonism

Journal of Hypertension

Volumn 30, Issue 7, 2012, Pages 1406-1413

  Calò, Lorenzo A ^a   Davis, Paul A ^b   Pagnin, Elisa ^a   Dal Maso, Lucia ^a   Caielli, Paola ^a   Rossi, Gian P ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

calcitonin gene related peptide; endothelial progenitor cells; heme oxygenase 1; hypertension; nitric oxide dependent vasodilation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; CALCITONIN GENE RELATED PEPTIDE; CD133 ANTIGEN; CD34 ANTIGEN; HEME OXYGENASE 1; NITRIC OXIDE; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; BARTTER SYNDROME; BLOOD FLOW; BRACHIAL ARTERY; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GITELMAN SYNDROME; HUMAN; HYPERTENSION; IMMUNOASSAY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VASODILATATION;

EID: 84862771518     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835414f7     Document Type: Article

References (43)

1. Calò LA. Vascular tone control in humans: the utility of studies in Bartter's/Gitelman's syndromes. Kidney Int 2006; 69:963-966. (Pubitemid 43372169)
2. Calò LA, Pessina AC. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens 2007; 25:259-264. (Pubitemid 46071919)
3. Naesens M, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D. Bartter's and Gitelman's Syndromes: From Gene to Clinic. Nephron Physiol 2004; 96:65-78.
4. Favero M, Calò LA, Schiavon F, Punzi L. Bartter's and Gitelman's diseases. Best Pract Res Clin Rheumatol 2011; 25:637-648.
5. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996; 12:24-30. (Pubitemid 26011315)
6. Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008; 40:592-599. (Pubitemid 351601207)
7. Calò LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC, et al. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's sydrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 2004; 89:4153-4157. (Pubitemid 39071528)
8. Wieland T, Lutz S, Chidiac P. Regulators of G protein signaling: a spotlight on emerging functions in the cardiovascular system. Curr Opin Pharmacol 2007; 7:1-7.
9. Calò LA, Pagnin E, Ceolotto G, Davis PA, Schiavo S, Papparella I, et al. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes. J Hypertens 2008; 26:938-945. (Pubitemid 351520981)
10. Semplicini A, Lenzini L, Sartori M, Papparella I, Calò LA, Pagnin E, et al. Reduced expression of regulator of G protein signaling-2 in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J Hypertens 2006; 24:1115-1124. (Pubitemid 43772320)
11. Calò LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D'Angelo A, et al. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. J Hypertens 2010; 28:111-118.
12. Pagnin E, Semplicini A, Sartori M, Pessina AC, Calò LA. Reduced mRNA and protein content of Rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes: relevance for the pathophysiology of hypertension. Am J Hypertens 2005; 18:1200-1205. (Pubitemid 41337973)
13. Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC, Calo LA. Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: relationship to angiotensin II signaling. J Hypertens 2004; 22:1963-1969. (Pubitemid 39336679)
14. Calò L, Sartore G, Bassi A, Basso C, Bertocco S, Marin R, et al. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome). J Hypertens 1998; 16:1001-1008. (Pubitemid 28367955)
15. Calò LA, Pagnin E, Davis PA, Sartori M, Semplicini A. Oxidative stress related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant 2003; 18:1518-1525. (Pubitemid 36939623)
16. Calò LA, Puato M, Schiavo S, Zanardo M, Tirrito C, Pagnin E, et al. Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. Nephrol Dial Transplant 2008; 23:2804-2809.
17. Calò LA, Montisci R, Scognamiglio R, Davis PA, Pagnin E, Schiavo S, et al. High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes). Are angiotensin II type 2 receptors involved? J Endocrinol Invest 2009; 32:832-836.
18. Calò LA, Facco M, Davis PA, Pagnin E, Maso LD, Puato M, et al. Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling. Hypertens Res 2011; 34:1017-1022.
19. Wu BJ, Midwinter RG, Cassano C, Beck K, Wang Y, Changsiri D, et al. Heme oxygenase-1 increases endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2009; 29:1537-1542.
20. Zhou Z, Peng J, Wang C-J, Li D, Li T-T, Hu C-P, et al. Accelerated senescence of endothelial progenitor cells in hypertension is related to the reduction of calcitonin gene-related peptide. J Hypertens 2010; 28:931-939.
21. Peng J, Lu R, Ye F, Deng H-W, Li Y-J. The heme oxygenase pathway is involved in calcitonin gene-related peptide-mediated delayed cardioprotection induced by monophosphoryl lipid A in rats. Regul Pept 2002; 103:1-7. (Pubitemid 34001630)
22. Reidy MA, Schwartz SM. Endothelial regeneration. III. Time course of intimal changes after small defined injury to rat aortic endothelium. Lab Invest 1981; 44:301-308. (Pubitemid 11156721)
23. Werner N, Priller J, Laufs U, Endres M, Bohm M, Dirnagl U, et al. Bone marrow derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 2002; 22:1567-1572.
24. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353:999-1007. (Pubitemid 41262334)
25. Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens 2005; 23:97-104. (Pubitemid 40128986)
26. Yao E-H, Fukuda N, Matsumoto T, Kobayashi N, Katakawa M, Yamamoto C, et al. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens Res 2007; 30:1119-1128.
27. Honda A, Matsuura K, Fukushima N, Tsurumi Y, Kasanuki H, Hagiwara N. Telmisartan induces proliferation of human endothelial progenitor cells via PPAR(-dependent PI3K/Akt pathway. Atherosclerosis 2009; 205:376-384.
28. Aizawa T, Ishizaka N, Taguchi J, Nagai R, Mori I, Tang SS, et al. Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats: possible role in renoprotection. Hypertension 2000; 35:800-806. (Pubitemid 30165329)
29. Datla SR, Dusting GJ, Mori TA, Taylor CJ, Croft KD, Jiang F. Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress. Hypertension 2007; 50:636-642. (Pubitemid 47442726)
30. Stocker R, Perrella MA. Heme oxygenase-1. A novel drug target for atherosclerotic diseases? Circulation 2006; 114:2178-2189. (Pubitemid 44747899)
31. Calò LA, Davis PA. Number and function of circulating endothelial progenitor cells and calcitonin gene-related peptide in hypertension: support from and opportunities in Bartter's and Gitelman's syndromes patients. J Hypertens 2010; 28:2169-2170.
32. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008; 60:79-127. (Pubitemid 351439218)
33. Davis PA, Pagnin E, Semplicini A, Avogaro A, Calò LA. Insulin signaling, glucose metabolism and the angiotensin II signaling system. Studies in Bartter's/Gitelman's syndromes. Diabetes Care 2006; 29: 469-471. (Pubitemid 44106550)
34. Calò LA, Davis PA, Palatini P, Semplicini A, Pessina AC. Urinary albumin excretion, endothelial dysfunction and cardiovascular risk: study in Bartter's/Gitelman's syndromes and relevance for hypertension. J Hum Hypertens 2007; 21:904-906. (Pubitemid 350020343)
35. Davis PA, Mussap M, Pagnin E, Bertipaglia L, Semplicini A, Calò LA. Early markers of inflammation in a high angiotensin II state. Results of studies in Bartter's/Gitelman's syndromes. Nephrol Dial Transplant 2006; 21:1697-1701. (Pubitemid 44063136)
36. Calò LA, Davis PA, Pagnin E, Schiavo S, Semplicini A, Pessina AC. Linking inflammation and hypertension in humans: studies in Bartter's/Gitelman's syndromes. J Hum Hypertens 2008; 22:223-225. (Pubitemid 351266494)
37. Fadini GP, Avogaro A. Cell-based methods for ex vivo evaluation of human endothelial biology. Cardiovasc Res 2010; 87:12-21.
38. Timmermans F, Plum J, Yo der MC, Ingram DA, Vandekerckhove B, Case J. Endothelial progenitor cells: identity defined? J Cell Mol Med 2009; 13:87-102.
39. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008; 28:1584-1595.
40. Fadini GP, Baesso I, Albiero M, Sartore S, Agostini C, Avogaro A. Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis 2008; 197:496-503.
41. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89:e1-e7.
42. Datla SR, Griendling KK. Reactive oxygen species, NADPH oxidases, and hypertension. Hypertension 2010; 56:325-330.
43. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27. (Pubitemid 20209468)